Despite decades of research and ever-increasing R&D spending, the overall probability success rate of oncology programs remains stubbornly low. 

Imaging biomarkers are an essential part of measuring the efficacy of potential new treatments in oncology studies. However, the methods of measuring tumour growth have not changed much since the RECIST protocol was developed in 2000. 

Our whitepaper compares the use of imaging biomarker methodologies such as RECIST 1.1 with novel tumour growth rate (TGR) modelling. Using this methodology eliminates the need for a comparable control arm which can reduce research costs. TGR modelling also more efficiently captures heterogeneous tumour measurements and whole-body tumour burden. 

• The limitations of current imaging methods
• Novel TGR modelling background
• TGR methodology
• Advantages of TGR modelling
• Considerations for using TGR modelling in your oncology research